Author

admin

Browsing

The shocking capture and extradition of former Venezuelan President Nicolas Maduro and his wife over the weekend is the culmination of months of US pressure on the regime. President Trump and other administration officials have labeled Maduro and his close associates “narco-terrorists, accusing him of leading a huge criminal organization and profiting by violating US laws, selling large quantities of illegal narcotics which may have potentially killed Americans. 

But while the future of the Venezuelan regime is uncertain, it is worth taking a few minutes to understand how Venezuela got to where it is today and what Americans can learn from its descent into a tyrannical/criminal regime.

The time for a warning may be especially appropriate. Zohran Mamdani’s election as New York City’s next mayor and Katie Wilson’s election as mayor of Seattle, both late last year, have people worrying about a surge in socialist sentiment across the US. Both Mamdani and Wilson openly campaigned as democratic socialists who believe: “No problem is too big, no issue is too small for the government” and “We will replace the frigidity of rugged individualism with the warmth of collectivism.” 

Many with a lick of sense correctly criticize the naivety of these socialist economic policy ideas and collectivist sentiments. But fewer recognize the true horrors that can be unleashed by entitled college graduates voting for massive wealth redistribution.  

The tragedy of Venezuela serves as a cautionary tale.

Socialism plays the major role in the story of Venezuela’s descent into poverty, desperation, and organized crime (Tren de Aragua). David Friedberg, a venture capitalist and a member of the All-In Podcast, recently interviewed Nobel Peace Prize winner María Corina Machado about the fraudulent 2024 national election in Venezuela — highlighting the tragedy of socialism and the resulting tyranny in Venezuela. 

Twenty-five years ago, its GDP was roughly $4,800 per person. In 2014, it was nearly $16,000. But the latest estimates for 2024 and 2025 are about $4,000 per person — roughly 20 percent less than in 2000 and a shocking 75 percent less than in 2014. Poverty rates in Venezuela have skyrocketed from less than a quarter of its population to over half. Yet, Venezuela has the largest known oil reserves of any country in the world – an estimated 300 billion barrels — 10 percent more than Saudi Arabia and seven times more than the United States. 

GDP per capita in Venezuela, 1960-2024. World Bank data.

At least seven million Venezuelans have fled the country in the past ten years, most of them college-educated. The Maduro regime was a criminal enterprise. Besides Maduro himself, several of his family members have been arrested for trafficking cocaine. The government stole the property of its people as well as plundering the country’s natural resources. The regime has also been accused of cooperating with drug trafficking and cartel activity — hence the Trump administration’s focus on Venezuelan gangs, and trafficking described as “narco-terrorism.” 

Venezuela’s 2024 presidential election showcased remarkable courage and ingenuity on the part of those who opposed the Maduro regime. It was also the clearest expression yet of how utterly criminal and corrupt Maduro was. The main opposition candidate, María Corina Machado, after a resounding victory in the primaries, was prohibited by the government from running.  

Her lesser-known proxy, Edmundo González, still won overwhelmingly. And we know he won because Venezuelans documented their election results in incredible ways and reported those results to the rest of the world. The European Union, the European Parliament, and Human Rights Watch all rejected Maduro’s victory, as did other election watchers, who declared González the winner. 

Yet today, González is in exile, and many of those who worked on the campaign are in prison or worse. Maduro claimed victory, against all evidence, and threw dissidents and those who supported them, or even associated with them, into prison. We see truly Mafia-like behavior in disappearing and blacklisting people simply for doing business with the “opposition.” A United Nations report found “evidence of unlawful executions, enforced disappearances, arbitrary detentions and torture” in Venezuela under the Maduro regime.

The state of things in Venezuela is dire and complicated. Much has been written about the highly tenuous legality of military strikes on Venezuelan drug traffickers. And much more will be written about the apprehension of Maduro and his wife in the dead of the night. While the Trump administration should do more to align with constitutional norms and the rule of law, this is not exactly a repeat of the drug war of the 1990s. 

The Maduro regime was actively supporting oppressive parties across Latin America as well as strengthening drug cartels that, in many countries, basically constitute paramilitary forces. Those who want to advance freedom, property rights, and prosperity across the western hemisphere should not overlook the geopolitical force of Venezuela. 

It’s tragic how far Venezuela has fallen. From a prosperous, successful, cultured society, it has become destitute, crime-ridden, and ruled by military thugs. But its initial step towards modern serfdom was much more innocent — and should serve as an eerie warning for the collectivist inclinations of the young and entitled. 

Hugo Chávez, the architect of Venezuelan socialism and tyranny, paved the way for Nicolas Maduro to rule by military fiat. Chávez, though, was popularly elected and portrayed himself as an outsider and a man of the people — someone who would refuse to go along with the corrupt “neoliberalism” that he claimed had disenfranchised so many.  

Sound familiar? 

There has been a lot of talk about how hard young people have it in the US. Buying a house is more difficult, because homes are more expensive and financing costs are high. Unemployment among 20-24-year-olds is more than double the unemployment rate for the rest of the population. Student debt continues to rise at an alarming rate — both in aggregate and for individual young college graduates.

But the recent interview with María Corina Machado reveals how the young and entitled, and their sympathizers, miss the central justification of a free society. Machado notes that the young socialists in Venezuela when they were warned to watch out, would “always answer, ‘Venezuela is not Cuba. That’s not going to happen to us.’ And at the end, look at the disaster and devastation.” 

Socialists have exploited this discontent. In New York City, Mamdani tapped into the frustration with housing, with jobs, with rent, with prices, and with uneven wealth gains in the stock market. Income and wealth inequality frustrate many young people. Declining income mobility frustrates them. They increasingly feel like the deck is stacked against them. 

Although such concerns are real, they hardly justify a socialist impulse — and not just because socialism won’t fix these problems. What these young idealists (or entitled ignoramuses) don’t know is the story of Venezuela and nearly a dozen other countries who’ve tread this path already. In Venezuela, they don’t just have an expensive housing problem, or an income mobility problem, or an income and wealth inequality problem.  

They have much deeper problems: lack of hope and lack of opportunity. In the United States, even with the challenges mentioned above, people can still find jobs, even if those jobs pay less than they would like. They can usually choose to work more hours if they want to make more money. They can move about freely. They are not beaten or imprisoned for social media posts or for supporting the “wrong” candidates. They can improve their lives. They can build for the future. Even if achieving success has become harder than in the past, that is far different from success not being possible. 

And that’s the real danger, and the real tragedy, of Venezuela. Socialism isn’t just about inefficiency and becoming poorer — though it does cause both those things. Socialism leads to tyranny where the worst rise to the top, civil society is destroyed by political power, and the opportunity to improve one’s life doesn’t just diminish, it is extinguished. 

Although Venezuelans’ future prospects have brightened considerably with the removal of Maduro, we should continue to point out the dangers of socialist regimes with increasing urgency to generations of people who know little about history or global affairs, care even less, and are merrily traipsing down the Road to Serfdom

Bitcoin and other cryptocurrencies are widely – but wrongly – panned as unregulated casinos or Ponzi schemes that create no real value. For example, US Senator Elizabeth Warren called crypto a “threat to financial stability,” while the UK’s Treasury Select Committee said that cryptocurrency ownership “more closely resembles gambling than a financial service.”

While some cryptocurrencies are mainly speculative, many serve specific business or functional purposes. We can identify some of the value created by cryptocurrencies by breaking them into four general categories: Bitcoin, stablecoins, meme coins, and utility tokens.

1. Bitcoin

Bitcoin (BTC) is the original cryptocurrency. It is the base token of the Bitcoin protocol, a decentralized proof-of-work blockchain based on the 2008 whitepaper by Bitcoin’s anonymous founder Satoshi Nakamoto. The protocol has a limited supply, with an eventual maximum of 21 million bitcoins.

Unlike most cryptocurrencies, Bitcoin has only one purpose: to be used as money – or, more specifically, as a system of payment. It has no other features. The Bitcoin network is decentralized, which makes it highly resilient and hard to disrupt, though coin prices can be quite volatile.

With a market capitalization of around $2 trillion, Bitcoin is by far the largest cryptocurrency by market value. No other blockchain has anywhere near its history, its reliability, or its dedicated flock of fans and users. Bitcoiners often say that “Bitcoin is not crypto” because it is so fundamentally different from other blockchains that it deserves a category of its own.

2. Stablecoins

Stablecoins are tokens whose value is tied to a particular asset, most commonly the US dollar. They are widely used in electronic payments since they provide the benefits of blockchain-based payments without Bitcoin’s price volatility. Stablecoin payments are especially prominent in countries with unstable national currencies, whose governments cannot be trusted to maintain the value of their money.

The two most widely used stablecoins, Tether (USDT) and Circle’s USDC, have market capitalizations of about $148 billion and $62 billion, respectively. Both tokens are readily redeemable for US dollars. Circle is regulated as a money transmitter in the United States. Tether is a foreign entity, but is in the process of launching a regulated US subsidiary.

The opposite of gambling, stablecoins are safe, stable assets that serve as an electronic version of US dollars.

3. Utility tokens

Utility tokens are cryptocurrencies created by blockchains that provide some utility or service.

One example is Filecoin (FIL), which offers online storage, likeiCloud or Microsoft OneDrive, but on a decentralized public blockchain. The Filecoin blockchain provides safe and private file storage on the decentralized Filecoin network. The FIL token is used to pay for storage and is paid to participants to provide storage space on the Filecoin network.

A subset of utility tokens known as Decentralized Physical Infrastructure (DePIN) uses decentralized blockchains as a replacement for government or corporate-based infrastructure.  The Helium network (HNT), for example, provides a block-chain based marketplace for buying, selling, and transmitting WiFi and mobile phone data.

In addition, the decentralized finance (DeFi) industry is building a parallel financial system on blockchain technology, which is cheaper and more transparent than traditional exchanges. Larry Fink, CEO of Blackrock, the world’s largest asset manager, has said that the tokenization of traditional assets will be “the next major evolution in market infrastructure.”

Unsurprisingly, utility tokens – those with actual functionality and business purposes – tend to be the category most attractive to major cryptocurrency investment funds and venture capitalists.

4. Meme coins

There is one category of crypto tokens meant purely for speculation: Meme coins. These tokens have no functional purpose and no intrinsic value aside from the fun of trading. They are based on “meme” characteristics, like symbol or story that drives their prices. Many use pictures of dogs, frogs, and hats. The most popular meme coin DOGE, represented by a picture of a Shiba Inu dog and frequently referenced by Elon Musk, has a market cap above $26 billion. Another token, FARTCOIN, is based on, well, fart jokes.

There are political meme coins for candidates like BODEN and TREMP, whose prices bounced around before the 2024 elections as candidates moved in and out of favor, with both eventually crashing. After the election but before taking office, President Trump launched his own meme coin TRUMP, which peaked in late January, then lost 80 percent of its value within a few months.

Most meme coins trade for the fun of participating in a shared joke or the excitement of betting that the price will rise. They are indeed gambling in the truest sense, but despite these tokens being amongst the most well-known to non-crypto folk, this category of tokens represents only a small segment of the crypto market.

While there is certainly much speculation in cryptocurrencies, as in all financial markets, the cryptocurrency industry is more than meme coins. Bitcoiners hope Bitcoin will become the world’s dominant means of payment or at least a common reserve currency. Stablecoins provide an efficient means of payment and a relatively stable store of value, at least as far as the US dollar does. Utility tokens create real value or serve some business function.

Collectively, cryptocurrencies provide a variety of functions and use cases, ranging from specific business purposes to no purpose at all. Users can gamble if they want to, or they can make more informed strategic investments. Crypto is more than just a meme coin casino.

From established players to up-and-coming firms, Canada’s pharmaceutical landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.

1. HLS Therapeutics (TSX:HLS)

Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.

HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May.

The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo’s commercial launch in Q2 2026.

Along with the approval, Health Canada issued a notice of non-compliance for its Nexlizet cholesterol-reducing treatment. According to HLS, the decision was related to chemistry, manufacture and controls data, not clinical data or safety.

Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

2. Satellos Bioscience (TSXV:MSCL)

Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue.

Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In Q4 2025, Satellos administered the first dose to a patient in its 11-month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.

On December 9, the company received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.

3. Knight Therapeutics (TSX:GUD)

Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00

Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec. It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.

The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to Knight’s Canadian roster.

The additions, helped drive 32 percent revenue growth year-over-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company’s top revenue-contributor within two years.

4. BioSyent (TSXV:RX)

Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90

BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women’s wellness. Its flagship brand, FeraMAX, has been Canada’s leading iron supplement for over a decade.

The company’s 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its Q3 earnings report. BioSyent’s sales grew 19 percent year-over-year in Canada and 94 percent in the international market.

5. NurExone Biologic (TSXV:NRX)

Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66

NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023.

The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in the second half of 2026, targeting patients with traumatic injuries.

It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.

The company announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to the release, ‘The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.’

In December, the company began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Here’s a quick recap of the crypto landscape for Monday (January 5) as of 9:00 p.m. UTC.

Get the latest insights on Bitcoin, Ether and altcoins, along with a round-up of key cryptocurrency market news.

Bitcoin and Ether price update

Bitcoin (BTC) was priced at US$94,127.01, up by 3.2 percent over 24 hours.

Bitcoin price performance, January 6, 2025.

Bitcoin price performance, January 6, 2025.

Chart via TradingView.

Bitcoin started Monday strong, rising above US$92,000 in early trading before briefly breaking US$94,600, signaling a potential shift in near-term momentum after a bruising finish to 2025.

Research firm 10X said the move reflects a return to more normalized trading volumes and early signs of renewed institutional positioning at the start of the year. The firm notes that Bitcoin is holding above key moving averages, with the 21 day line emerging as a critical support level for maintaining upside bias.

It added that the shift suggests growing expectations for a push toward the US$100,000 level. The rebound follows three consecutive monthly declines — a historically rare pattern that has often preceded January recoveries.

“The strength across crypto and traditional safe havens reflects a rebalancing phase driven by geopolitical risk and liquidity positioning,” said Lacie Zhang, a research analyst at Bitget Wallet.

“In this setup, Bitcoin has room to push toward US$105,000, while Ethereum could test US$3,600, as traders balance inflation risks with crypto’s deflationary characteristics and long-term adoption narrative.’

Zhang said DeFi is currently driving significant growth, with protocols such as Uniswap (UNI) and Aave (AAVE) seeing benefits from improved governance, new revenue-sharing frameworks and institutional investor involvement.

“For large-cap altcoins, XRP and Solana stand out: XRP’s role in cross-border payments and improving regulatory clarity, combined with ETF inflows, could support price ranges of US$5 – US$10, while Solana’s high-throughput ecosystem and network expansion position it for US$500 – US$800 over the next growth phase.

“The renewed surge in memecoin activity reflects improving retail risk appetite,” she added. “It’s not a long-term thesis, but often a precursor to liquidity rotating into higher-quality, utility-driven altcoins as the cycle matures.”

Ether (ETH) was priced at US$3,239.82, up by 3.2 percent over the last 24 hours.

Altcoin price update

  • XRP (XRP) was priced at US$2.31, up by 10.4 percent over 24 hours.
  • Solana (SOL) was trading at US$137.92, up by three percent over 24 hours.

Today’s crypto news to know

Crypto investment products pull in US$47.2 billion in 2025

Global crypto exchange-traded products attracted US$47.2 billion in net inflows in 2025, falling just short of the prior year’s record despite a noticeable slowdown in Bitcoin demand, according to CoinShares.

Bitcoin-focused products added US$26.9 billion, a sharp drop from 2024 levels, as price weakness dampened inflows and modest interest emerged in short-bitcoin vehicles. The cooling in Bitcoin was offset by a surge into select altcoins, led by Ethereum products, which posted US$12.7 billion in inflows.

Meanwhile, XRP and Solana funds followed closely as each recorded multibillion-dollar inflows and triple-digit percentage growth year over year.

Japan signals crypto integration across traditional markets

Satsuki Katayama, Japan’s finance minister, has signaled stronger government backing for integrating digital assets into the country’s stock and commodities exchanges.

Speaking at the Tokyo Stock Exchange, she emphasized the role of exchanges in expanding public access to blockchain-based assets and modern investment tools. She pointed to the US experience with crypto-linked exchange-traded funds (ETFs) as a reference point, even as Japan currently lacks domestically listed crypto ETFs.

Katayama described 2026 as a “digital year,” pledging policy support for exchanges adopting advanced trading technologies. The remarks build on regulatory reforms already underway, including discussions on allowing banks to hold crypto assets and the approval of Japan’s first yen-pegged stablecoin.

Bitget’s tokenized stock milestone and TradFi launch

Bitget’s new Universal Exchange vision has reached two major milestones that signal a major shift in how digital and traditional assets are traded in one place. Bitget announced last week that its tokenized stock volume surpassed US$1 billion, with 95 percent of that total volume occurring in December alone.

Building on that momentum, and following a successful private beta with over 80,000 users, today Bitget officially opened its TradFi trading suite to the public, allowing customers access to 79 different instruments across forex, metals, indices and commodities. These products are traded as contracts for difference and are settled entirely in USDT, meaning crypto-native traders can execute macro strategies without leaving the platform or converting to fiat currency.

During the test phase, XAU/USD recorded over US$100 million in single-day trading volume, one of the highest daily figures observed during the beta.

“Traders want the flexibility to choose between assets in a unified ecosystem,” said Chen.

“They want the freedom to move between crypto and traditional markets as conditions change. TradFi going public is about giving them that accessibility in one place, without friction.”

The move signals a broader shift in how exchanges are evolving, not just as venues for speculation, but as comprehensive gateways to global markets under a unified trading experience.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Perth, Australia (ABN Newswire) – Altech Batteries Ltd (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) announced that binding conditional funding approval in the amount of 46.11 million Euro has now been granted for the CERENERGY(R) Sodium-Chloride Solid-State battery project in Saxony, Germany. The grant approval materially derisks project funding and supports progression toward construction of the planned 120 MWh CERENERGY(R) battery manufacturing facility in Saxony, Germany.

Highlights

– Altech Batteries GmbH’s CERENERGY(R) battery project has received conditional binding funding approval under Germany’s federal ‘STARK’ economic development program.

– The approval relates to a grant covering approximately 30% of eligible project CAPEX, with funding of up to EUR46.11M.

– The funding commitment is conditional on achieving full project financial close by 30 June 2026 and parliamentary approval of funds under Germany’s 2026 Federal Budget.

Conditional Binding Funding Commitment

The funding is being provided as part of the federal STARK program, which is supported by the Federal Ministry for Economic Affairs and Energy in cooperation with the EU. The aim of this program is to lead regions undergoing structural change into an ecologically, economically and socially sustainable future.

With the approval of the funding, the project has successfully completed the second and decisive stage of the approval process. The funding covers approximately 30% of the eligible investment costs and represents a significant milestone for the construction of the planned 120 MWh CERENERGY(R) battery factory in Germany.

This decision underscores the importance of the innovative CERENERGY(R) technology, which is being developed in collaboration with the Fraunhofer Society. The Sodium-Chloride Solid-State battery offers a safe, sustainable and strategically independent alternative to lithium-ion batteries and is expected to play an important role in future stationary energy storage solutions – especially for the European market.

Mr Daniel Raihani, Managing Director & Chief Executive Officer, commented ‘Securing conditional binding funding approval of up to EUR46.11 million under Germany’s STARK program is a major milestone for the CERENERGY(R) project. The support reflects the strategic importance of establishing advanced, nonlithium energy storage manufacturing capability in Europe and recognises the technical progress achieved to date in collaboration with Fraunhofer IKTS.

‘Importantly, the grant materially de-risks the project’s capital structure by covering approximately 30% of eligible investment costs and provides a strong foundation as we progress toward full project financing and construction of the planned 120 MWh production facility in Saxony, Germany.

‘We remain focused on completing financial close by mid-2026 and advancing the CERENERGY(R) technology toward commercial deployment to support long-duration, safe and sustainable stationary energy storage solutions for the European market’.

As is customary for projects of this size, the funding commitment is subject to final financial close of the CERENERGY(R) battery project by June 2026 and budgetary approval of the funds in the 2026 federal budget.

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/918BT5H8

About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS (‘Fraunhofer’) to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech’s land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

Source:
Altech Batteries Ltd

Contact:
Daniel Raihani
Managing Director
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

Martin Stein
Chief Financial Officer
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com

News Provided by ABN Newswire via QuoteMedia

This post appeared first on investingnews.com

Investor Insight

Juggernaut Exploration is an early-stage explorer and project generator with a compelling investment story, focused on unlocking high-grade precious and base metal discoveries in the prolific Golden Triangle of northwestern British Columbia.

Overview

Juggernaut Exploration(TSXV:JUGR,OTCQB:JUGRF,FSE:4JE) is a precious metals explorer focused on northwestern British Columbia’s Golden Triangle, a globally recognized district for world-class porphyry, VMS, and high-grade gold systems. The company operates in a geopolitically stable jurisdiction with excellent infrastructure, adjacent to Newmont’s Galore Creek project and in proximity to major road and airstrip developments.

Map showing Juggernaut properties and routes in British Columbia, labeled BIG ONE and BINGO.

The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of British Columbia’s most prolific mineral belt.

The company’s current strategy focuses on aggressive exploration at its flagship Big One project, where the rapid abatement of glacial cover led to the discovery of over 200 mineralized veins in a matter of days. The scale of the system, coupled with strong geophysical and geochemical signatures, points to a significant buried porphyry system.

Backed by world-renowned geologist Dr. Quinton Hennigh, Juggernaut was founded by the team behind Goliath Resources, which returned 2,400 percent to early investors in just 20 months.

Company Highlights

  • The Big One property has uncovered a 15-km gold-rich porphyry system, described as a “highway of gold,” adjacent to Newmont’s $100 billion Galore Creek project.
  • Founded by the team behind Goliath Resources, which returned 3,400 percent to early investors in just 20 months. World-renowned geologist Dr. Quinton Hennigh supports Juggernaut.
  • Crescat Capital is a cornerstone investor, holding a 19.99 percent stake and providing both financial and technical backing.
  • The company controls three 100 percent owned projects – Big One, Midas, and Bingo – totaling nearly 60,000 hectares in the heart of the Golden Triangle in British Columbia.
  • With $12.5 million recently raised, the 2025 field season is fully funded. The upcoming campaign aims to scale and define the scope of the porphyry system discovered in just five days of boots-on-the-ground work.
  • 5-Year Drill Permit Secured: A valid 5-year drill permit is in place for the Big One Property in British Columbia’s Golden Triangle, in good standing through March 31, 2031.
  • 2026 Inaugural Drill Program: The company is planning a fully funded drill program to test multiple gold-rich, shear-hosted vein targets identified at surface within the newly discovered, district-scale Eldorado System and Gold Swarm discoveries, targeting depth extensions in the third dimension.
  • Over 70 percent of the company’s shares are held by management, insiders and accredited investors. The company is debt-free.

Key Projects

Big One

Map showing the Juggernaut Exploration

The Big One project is Juggernaut’s flagship asset located in the heart of British Columbia’s Golden Triangle. The property spans 36,989 hectares of world-class geological terrain, with 95 percent of its remaining unexplored.

The project benefits from rapid glacial and snowpack abatement, which has recently exposed a vast mineralized system previously hidden under ice. This includes the newly identified Eldorado porphyry system, a high-grade, multi-kilometer corridor with grades reaching up to 79.01 grams per ton (g/t) gold and 3,157 g/t silver. More than 200 quartz-sulphide veins, containing semi-massive to massive chalcopyrite, sphalerite and galena, have been identified within a 4 km x 1 km alteration footprint, with coincident geophysical anomalies suggesting the presence of a large, buried mineralizing system at depth.

Map of Juggernaut Exploration

The Big One project qualifies for the Critical Mineral Exploration Tax Credit and is strategically located adjacent to key infrastructure, including the Scud airstrip and a new $45 million government-funded road within 12 km of the site.

In 2025, Juggernaut Exploration received a 5-year drill permit for the Big One property. The permit is in good standing until March 31, 2031. The company is planning a drill program targeting several extensive gold-rich shear-hosted veins confirmed on surface in the newly discovered district-scale Eldorado System and Gold Swarm discoveries. These strong drill targets are planned to be tested in the third dimension during the fully-funded inaugural drill program in 2026.

Map of Juggernaut Exploration

Newly discovered drill ready El Dorado System

Midas

The Midas property covers 20,803 hectares in a geologically favorable setting for volcanogenic massive sulphide (VHMS) deposits, particularly those resembling the high-grade Eskay Creek system. Drilling at the Kokomo zone has intercepted significant VHMS-style mineralization, including standout results such as 8.27 g/t gold equivalent over 11.03 meters (MD-24-47) and 6.85 g/t gold over 9 meters (MD-18-08). The mineralized zone remains open to the north, and the company plans to step out aggressively with additional drilling.

Midas is considered a strong near-term value generator with potential for scale through further discovery.

Bingo

The Bingo property, although smaller in footprint at 1,008 hectares, is located in a structurally favorable setting for shear-hosted gold systems. The project features a 700-meter x 400-meter mineralized zone characterized by consistent sulphide mineralization. Sampling has confirmed an average mineralized width of 7 meters with grades averaging 5.67 g/t gold equivalent. The presence of strong K-spar alteration in the northeast quadrant of the property suggests proximity to a porphyry feeder system, making Bingo a compelling target for both high-grade, shear-hosted and porphyry-style exploration.

Management Team

Manuele (Lele) Lazzarotto – President and Chief Operating Officer (COO)

Manual Lazzarotto, Ph.D., has over a decade of experience in the mineral exploration industry, taking projects from inception to defined deposits. He has extensive experience in volcanogenic massive sulphide deposits and gold systems in Canada. Most recently, Lazzarotto has acted as chief geologist, instrumental in the discovery of Goliath Resources’ Surebet Discovery from 2019 to 2025. He holds a BSc and an MSc in Earth Sciences from ETH Zurich, Switzerland, and a PhD in Metamorphic Petrology from the University of Calgary, Canada.

Dan Stuart – CEO and Director

Dan Stuart has over 30 years of experience in capital markets, having raised more than $500 million for natural resource companies. He is a founding member and financier of several private mineral syndicates, including the J2 Syndicate behind Goliath Resources. Stuart is recognized for his investor acumen and has established strong institutional relationships across North America, Europe, Asia, and the Middle East. Under his leadership, Juggernaut secured cornerstone funding from Crescat Capital and Dr. Quinton Hennigh while simultaneously building a platform for rapid discovery-driven growth.

Jim McCrea – Director

Jim McCrea brings 25 years of exploration and resource estimation experience. Notably, he worked on orebody modeling and resource estimation at Cumberland Resources, which was acquired by Agnico Eagle for $710 million. His deep expertise in geology and modeling helps guide exploration targeting and resource development.

William Jung – Director and CFO

A former chartered accountant with over 35 years of experience in finance, William Jung has managed several publicly listed companies on the TSX. His oversight ensures financial discipline, compliance, and strategic capital allocation.

Peter Bryant – Director

Peter Bryant is a seasoned international investment banker with 45 years of experience, including senior roles at Standard Chartered Group, Hill Samuel Group, and Guinness Mahon Holdings in London. His presence brings strong governance and capital markets insights to the board.

Chris Verrico – Director

Chris Verrico has over two decades of experience managing mineral exploration and infrastructure projects in remote northern regions, including British Columbia, Yukon and Nunavut. His knowledge of field operations and community engagement is critical to project execution.

Bill Chornobay – Program Manager

Bill Chornobay has over 30 years of experience in mineral exploration and has been directly involved in discoveries resulting in more than $1 billion in value. He played a pivotal role in the Surebet discovery for Goliath Resources and now leads on-ground execution at Juggernaut.

Dr. Quinton Hennigh – Technical Advisor

A globally respected exploration geologist, Dr. Quinton Hennigh has over 30 years of experience with major mining companies, including Homestake, Newcrest and Newmont. He is currently the chairman of Novo Resources and serves as a technical advisor to Crescat Capital. His guidance has helped validate and shape the exploration strategy at Juggernaut.

Dr. Manuele Lazzarotto – Senior Consulting Geologist

Dr. Manuele Lazzarotto has eight years of experience advancing early-stage exploration projects into defined resources, particularly in VMS and gold systems. He played a critical technical role in the Surebet discovery and brings valuable geological and structural insight to Juggernaut’s targeting approach.

This post appeared first on investingnews.com

A select group of lawmakers received their first closed-door briefing on Capitol Hill on Monday following the Trump administration’s weekend military strikes in Venezuela and the capture of President Nicolás Maduro — a meeting that quickly divided along political lines.

The roughly two-hour meeting deep in the bowels of Congress featured top administration officials providing a classified briefing to congressional leaders and the chairs and ranking members of the armed services, intelligence and foreign relations committees. 

None of the Trump officials, who included Secretary of State Marco Rubio, Attorney General Pam Bondi, CIA Director John Ratcliffe, Joint Chiefs of Staff Chair Gen. Dan ‘Raizin’ Caine and Secretary of War Pete Hegseth, spoke after the meeting. 

But a handful of lawmakers did, and questions still lingered about what exactly would come next for U.S. involvement in the country, if other similar operations would be carried out across the globe, and who exactly was running Venezuela.

House Speaker Mike Johnson, R-La., said that there was no expectation that the U.S. would be on the ground, nor would there be any ‘direct involvement in any other way beyond just coercing the interim government to to get that going.’

‘We are not at war,’ Johnson said. ‘We do not have U.S. armed forces in Venezuela, and we are not occupying that country.’

‘This is not a regime change,’ he continued. ‘This is a demand for change of behavior by a regime. The interim government is stood up now, and we are hopeful that they will be able to correct their action.’

House Foreign Affairs Committee Chair Brian Mast, R-Fl., echoed Johnson, and reiterated that the operation was a ‘specific law enforcement function that took place that took a significant obstacle out of the way for the Venezuelan people to go chart a new future.’ 

He didn’t expect further military action from the Trump administration in the country, either. 

‘These things are done before breakfast,’ Mast said. ‘They don’t do protracted war operations.’

However, Senate Minority Leader Chuck Schumer, D-N.Y., countered that the lengthy meeting ‘posed far more questions than it ever answered.’ 

One growing point of contention among lawmakers is just how directly involved the U.S. will be, given that Trump said that the U.S. would govern the country until a proper transition of power happened. 

Schumer said that the plan presented behind closed doors or the U.S. running Venezuela ‘is vague, based on wishful thinking and unsatisfying.’

‘I did not receive any assurances that we would not try to do the same thing in other countries,’ he said. ‘And in conclusion, when the United States engages in this kind of regime change and so called nation building, it always ends up hurting the United States. I left the briefing feeling that it would again.’

Schumer, along with Sens. Tim Kaine, D-Va., Adam Schiff, D-Calif., and Rand Paul, R-Ky., plan to force a vote later in the week on a war powers resolution that, if passed, would require the administration to get congressional approval before taking further military action in Venezuela. 

Senate Majority Leader John Thune, R-S.D., said that he was satisfied with the briefing and that ‘it was a very comprehensive discussion.’

Lawmakers will get another bite at the apple later in the week when Trump officials again return to Congress to provide a full briefing to lawmakers on Operation Absolute Resolve. 

Sen. Mark Warner, D-Va., and the top-ranking Democrat on the Senate Select Committee on Intelligence, lauded the military for a ‘brilliant execution’ of the mission, and noted that the region was better off without Maduro.

But, like Schumer, he was still searching for the next step. 

‘The question becomes, as policymakers, what happens the day after,’ Warner said. 


This post appeared first on FOX NEWS

David Morgan, publisher of the Morgan Report, weighs in on silver’s record-setting price rise and what could be next for the white metal heading into 2026.

‘We’re still in price discovery. I truly believe that,’ he said.

‘What the true price of silver is in US dollars, Canadian dollars, I do not know. I think it’s north of $100 in US dollar terms, but it could be much higher than that.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Today’s pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry’s major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2025, 46 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 50 such approvals in 2024.

Big pharma largely steals the show when people discuss pharmaceutical companies, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Read on to learn more about their activities this year.

1. Galectin Therapeutics (NASDAQ:GALT)

Year-to-date gain: 211.45 percent
Market cap: US$263.08 million
Share price: US$4.08

Galectin Therapeutics is developing therapies for patients with chronic liver disease and cancer.

The clinical-stage biopharma company’s lead drug candidate, carbohydrate-based belapectin, targets multiple inflammatory, fibrotic and malignant diseases by inhibiting the galectin-3 protein. Belapectin has been granted fast-track designation by the FDA.

In 2025, Galectin Therapeutics reported positive topline data from its Phase 2b/3 trial evaluating the efficacy and safety of using belapectin intravenously in patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hyper tension. The results demonstrated that belapectin significantly reduced the development of new esophageal varices and stabilized liver stiffness, demonstrating potential to halt the progression of MASH cirrhosis.

Galectin is currently designing its pivotal Phase 3 study intended to support a formal new drug application. Based on a December 2025 response from the FDA, the company said it believes it has achieved alignment with the agency on the patient population for its upcoming registration-level trials.

2. CytomX Therapeutics (NASDAQ:CTMX)

Year-to-date gain: 136.63 percent
Market cap: US$375.74 million
Share price: US$2.38

CytomX Therapeutics is a clinical-stage biopharma firm with a focus on developing safer, more effective oncology treatments. It collaborates with a number of leading oncology firms, including Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN) and Moderna (NASDAQ:MRNA).

The company’s pipeline is based on its PROBODY therapeutic platform, which it uses to produce localized biologics that target tumors. This includes multiple treatment modalities such as antibody-drug conjugates, T-cell engagers and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051 and CX-801.

In mid-May 2025, CytomX’s share price shot up significantly after the company provided its Q1 business update and closed on a US$100 million underwritten offering of common stock.

In the update, CytomX included positive interim clinical results for an ongoing Phase 1 dose escalation study of its lead candidate, CX-2051, in advanced colorectal cancer. The company has initiated further Phase 1 dose expansions, with data expected out by Q1 2026. In its Q3 update, CytomX reported it plans to initiate a Phase 1b study of CX-2051 in combination with bevacizumab to treat colorectal cancer, also expected in the first quarter of the new year.

On May 19, the first patient was dosed in CytomX’s ongoing Phase 1 dose escalation study with CX-801 in combination with Merck & Company’s (NYSE:MRK) Keytruda in patients with metastatic melanoma. The company released initial translational data in November.

3. Eton Pharmaceuticals (NASDAQ:ETON)

Year-to-date gain: 25.37 percent
Market cap: US$450.53 million
Share price: US$16.80

Eton Pharmaceuticals is a high-growth pharmaceutical company developing treatments for rare diseases. Headquartered in Deer Park, Illinois, the company has successfully transitioned from a development-stage firm into a commercially focused entity with a diversified portfolio of orphan drugs.

2025 included the successful launch of KHINDIVI, the first FDA-approved oral solution formulation of hydrocortisone, in June. KHINDIVI was approved in May for pediatric patients five and older with adrenocortical insufficiency. The company is looking to expand the indication to younger patients with a revised formulation, and a bioequivalence study is expected to begin in early 2026.

The year also included high-performing relaunches of acquired assets Increlex, which treats a rare condition in which a child’s body does not produce enough growth factor-1, and the zinc therapy Galzin, a maintenance treatment for Wilson disease.

As of December, its portfolio included eight commercial products and five in its pipeline. The FDA is reviewing its new drug application for ET-600, with a decision scheduled for late February.

4. Fennec Pharmaceuticals (NASDAQ:FENC)

Year-to-date gain: 20.91 percent
Market cap: US$262.54 million
Share price: US$7.69

Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on preventing ototoxicity, meaning permanent hearing loss, in pediatric cancer patients undergoing cisplatin-based chemotherapy.

The company’s sole commercial product, Pedmark, is the first and only FDA-approved therapy specifically indicated to reduce the risk of hearing loss associated with cisplatin in patients one month of age and older with non-metastatic solid tumors.

Fennec experienced a pivotal year in 2025, marked by record revenue growth, entry into international markets and the elimination of corporate debt.

Additionally, data from a Phase 2/3 clinical study in Japan showed a significant reduction in the percentage of patients who experienced hearing loss, setting the stage for a 2026 global registration.

The company also began exploring its first major expansion into the adult cancer market through a new trial in metastatic testicular cancer.

5. Zevra Therapeutics (NASDAQ:ZVRA)

Year-to-date gain: 5.25 percent
Market cap: US$496.54 million
Share price: US$8.82

Zevra Therapeutics is a commercial-stage rare disease company that utilizes data-driven strategies to develop and commercialize transformational therapies for ultra-rare conditions.

Formerly known as KemPharm, the company rebranded in 2023 to reflect its evolution into a fully integrated pharmaceutical entity with a focus on high-unmet-need pediatric and metabolic disorders.

At the end of December, Zevra executed a strategic distribution agreement with Uniphar to provide its flagship product, Miplyffa, to patients outside of the US and Europe, broadening the drug’s global footprint. Miplyffa was approved by the FDA in 2024, and is indicated as a treatment for Niemann-Pick disease type C administered in combination with miglustat.

This announcement followed a strong Q3, in which the company reported a 605 percent year-over-year revenue increase, largely driven by the early success of Miplyffa.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com